PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval for MuGard in Korea
PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today that its Korean marketing partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi") (KSE: 128940) has received marketing approval in Korea from the country's Ministry of Food and Drug Safety ("MFDS") and the Korea Testing & Research Institute (KTR) for MuGard, its oncology supportive-care treatment for the management of oral mucositis. Under the terms of the previously announced marketing agreement, Hanmi will import MuGard from the...
View full press release